Skip to content

Clinical Observation on Therapeutic Efficacy of Longchai Formula Granule in Treating Chronic Hepatitis B

Clinical Observation on Therapeutic Efficacy of Longchai Formula Granule in Treating Chronic Hepatitis B

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005585
Enrollment
Unknown
Registered
2014-10-27
Start date
2011-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

test group:Longchai Formula Granule+matrine capsules placebo
Control:matrine capsules + Longchai Formula Granule placebo

Sponsors

Jiangsu Province Hospital of Integrated Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 63 Years

Inclusion criteria

Inclusion criteria: 1. Patient should conform to chronic hepatitis B standard that defined in the Guidance of Prevention and Treatment of Chronic Hepatitis B updated in 2010; Diagnositc standard of "zheng" differentiation for chronic hepatitis B according to Guiding principle of clinical research on new drugs of Chinese medicine; 2. age of 18-65 years; 3.not taking related medication within half of month; 4. voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients aged below 18 or above 65 years old; 2. Patients infected other types hepatitis virus at the same time; 3. Patients had autoimmune hepatitis or hepatitis caused by drug intoxication and ethylism; 4. Patients had been diagnosed with severe hepatitis, hepatic failure, cirrhosis, hepatocellular carcinoma, serious primary disease in cardiovascular and cerebrovascular, kidney, lung, endocrine system, hematopoietic system, and mental disease; 5. Patients were pregnant or lactating women; 6. Patients were allergic constitution or allergic to multiple drugs.

Design outcomes

Primary

MeasureTime frame
HBeAg;HBsAg;HBV-DNA;symptom score;ALT;AST;

Countries

China

Contacts

Public ContactZhu Fangshi
njfszhu@163.com+86 13655171138

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026